Imaging analysis of EGFR mutated cancer cells using peptide nucleic acid (PNA)-DNA probes

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Epidermal Growth Factor Receptor (EGFR) gene mutations, including exon19del E746-A750, T790M, and L858R, drive lung cancer progression and tyrosine kinase inhibitor (TKI) resistance.
• Accurate detection of these EGFR mutations is crucial for personalized treatment strategies in non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To develop and validate novel peptide nucleic acid (PNA)-DNA probes for the sensitive and specific imaging analysis of key EGFR mutations in lung cancer.
• To assess the feasibility of using these probes for distinguishing between different lung cancer cell lines harboring distinct EGFR mutations.

Main Methods:

• Development of three PNA-DNA hybrid probes, each comprising a fluorescein isothiocyanate (FITC)-conjugated PNA detection probe and a Dabcyl-conjugated DNA quencher probe.
• Validation of probe performance against target DNA and RNA sequences, assessing fluorescence signal generation.
• Application of the PNA-DNA probes in fluorescence in situ hybridization (FISH) assays to differentiate lung cancer cell lines with known EGFR mutations.

Main Results:

• The developed PNA-DNA probes successfully detected the target EGFR mutations (exon19del E746-A750, T790M, and L858R) with dose-dependent fluorescence signals.
• The probes demonstrated specificity in distinguishing between target DNA and RNA sequences.
• FISH analysis using the PNA-DNA probes enabled clear differentiation of three lung cancer cell lines (H1975, PC-9, and A549) based on their unique EGFR mutation profiles.

Conclusions:

• Novel PNA-DNA probes offer a promising tool for the accurate imaging analysis and detection of specific EGFR mutations in lung cancer.
• This approach facilitates the identification of distinct EGFR mutation statuses in lung cancer cell lines, supporting targeted therapy selection.